(Q36739767)

16 August 2017

1 reference

title

Immunotherapy of melanoma: a critical review of current concepts and future strategies (English)

1 reference

16 August 2017

1 reference

Adam I Riker

1

1 reference

16 August 2017

Soroosh Radfar

2

1 reference

16 August 2017

SuHu Liu

3

1 reference

16 August 2017

Yixiang Wang

4

1 reference

16 August 2017

Hung T Khong

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Biological Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

345-358

1 reference

New TNM melanoma staging system: linking biology and natural history to clinical outcomes

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Cancer immunotherapy: the interferon-alpha experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Immunity to melanoma antigens: from self-tolerance to immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

CpG motifs: the active ingredient in bacterial extracts?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Imiquimod in the treatment of lentigo maligna

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Topical imiquimod in the treatment of metastatic melanoma to skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Treatment of cutaneous metastatic melanoma with imiquimod 5% cream and the pulsed-dye laser

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Immunostimulatory DNA sequences necessary for effective intradermal gene immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Sentinel-node biopsy or nodal observation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with Stage IV melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Treatment of oligometastases after successful immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

Clinical protocol. Intra-Lesional rF-B7.1 versus rF-TRICOM vaccine in the treatment of metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.345

21 January 2018

Identifiers

DOI

10.1517/14712598.7.3.345

1 reference

16 August 2017

1 reference